Company Moves Aggressively into Worldwide Growth Industry of Life Sciences

TechTeam Global Inc. (Nasdaq: TEAM), a worldwide leader and provider of information technology outsourcing and business process outsourcing service, recently announced the launch of its new business unit, Global Life Sciences Business Unit.

In a news release to investors, the company said the formation of the new business unit is a response to growing demand and rapid opportunities in the life sciences industry. The formation of the Global Life Sciences Business Unit dovetails into the company’s previously formed Global Pharmaceutical Center of Excellence, supporting the pharmaceutical unit in its mission to provide services to fill unique needs of the pharmaceutical industry.

The new organization affords the company two important strategic changes, including increased focus and attention at the corporate level, and expands the scope of the operation beyond the pharmaceutical industry to serve the needs of the life sciences industry more broadly.

TechTeam serves clients in more than 500 clinical trials, in 25 languages, and across 25,000 sites, worldwide. The company offers eClinical technology to help clients with linguistics, user and application administration, site assessment, connectivity, solution provisioning, and training.

“Based on the level of customer interest and TechTeam’s unique ability to meet the needs of these customers, we see a tremendous opportunity to continue to grow this global business at an aggressive rate,” said Chris Donohue, the TechTeam corporate vice president who will lead the new business unit. “We have proven capabilities and already support some of the top names in this important industry. We are investing to add capacity, expand capabilities and to increase our visibility in the market.”

TechTeam is no stranger to the life sciences, having served the industry for a decade, but the formation of the Global Life Sciences Business Unit represents a large step in the company’s strategic move to capture one of the fastest growing segments of the world economy. Additionally, the need for research facilities to reduce costs at the product development stage has taken front stage, as companies find investors and underwriters seeking higher returns from capital more at risk in a world economy re-evaluating its increase need for risk-shifting toward technology development in all industries, especially biopharmaceutical and other life sciences.

“We have provided support to customers in the life sciences industry for 10 years,” says Gary J. Cotshott, TechTeam’s president and CEO. “The decision to create the Global Life Sciences Business Unit reflects our deep commitment to this industry, our customers and prospects, and their growing needs.”

“Last year we established a Global Pharmaceutical Center of Excellence. The formation of a full business unit on this foundation is the next logical step in the execution of our growth strategy. Looking to the future, we will continue to work closely with our customers to set priorities and evolve our capabilities in this area,” said Cotshott.

About TechTeam Global Inc.

TechTeam Global Inc. is a leading provider of IT outsourcing and business process outsourcing services to large and medium businesses, as well as government organizations. The company’s primary services include service desk, technical support, desk-side support, security administration, infrastructure management and related professional services.

TechTeam also provides a number of specialized, value-added services in specific vertical markets. Founded in 1979, TechTeam has nearly 3,000 employees across the world, providing IT support in 32 languages. TechTeam’s common stock is traded on the NASDAQ Global Market under the symbol “TEAM.”

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.